Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors
12.9.2019 09:30:00 EEST | Business Wire | Press release
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that Mr. Jeffrey Riley joined Gain Therapeutics as Independent Board Member.
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management.
“We are delighted to have Jeff join us as an independent board member,” said Dr. Khalid Islam, Chairman of the Board of Gain Therapeutics SA. “Jeff’s perspective, based on his distinguished career and leadership roles in R&D organizations and his transactional expertise will be very valuable to the board as the company seeks to execute on its global product discovery and development strategy."
“I am delighted to join Gain Therapeutics and support its endeavors to bring to patients brain penetrant small molecule able to regulate misfolded enzymes involved in rare pediatric diseases and in neurodegenerative disease for which high unmet medical needs still exist.” Said Mr. Jeffrey Riley, Independent Board member of Gain Therapeutics.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
https://www.gaintherapeutics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005392/en/
Contact information
For Gain Therapeutics SA
Dr. Manolo Bellotto, General Manager
+41 91 921 1524
mbellotto@gaintherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GigaDevice Extends European Reach with SEMITRON Partnership for DACH region12.2.2026 11:52:00 EET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has entered into a distribution agreement with SEMITRON, a leading electronic component distributor that specializes with a focus on the DACH region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203746978/en/ Under the terms of the deal, SEMITRON is set to supply both GigaDevice's leading Flash, MCU, power and sensor lines in conjunction with field application engineering support to customers in the industrial, automotive and communication technology sectors. In particular, SEMITRON offers professional test house services, technical know-how and local on-the-ground expertise and support. The partnership further extends GigaDevice's reach into this major European market, with on the ground support in Germany, Austria, Switzerland. Jürgen Rohland, Managing Director of SEMITRON W. Röck Gmb
Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing12.2.2026 11:48:00 EET | Press release
Samsung Electronics Co., Ltd., a global leader in advanced memory technology, today announced that it has begun mass production of its industry-leading HBM4 and has shipped commercial products to customers. This achievement marks a first in the industry, securing an early leadership position in the HBM4 market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212674509/en/ Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing By proactively leveraging its most advanced 6th-generation 10 nanometer (nm)-class DRAM process (1c), the company achieved stable yields and industry-leading performance from the outset of mass production — all accomplished seamlessly and without any additional redesigns. “Instead of taking the conventional path of utilizing existing proven designs, Samsung took the leap and adopted the most advanced nodes like the 1c DRAM and 4nm logic process for HBM4,” said Sang Joo
Sisvel Website Now Available in Chinese and Japanese12.2.2026 11:30:00 EET | Press release
Chinese and Japanese language versions of the Sisvel corporate website are now live, delivering an enhanced experience for users in two of the world’s key technology markets. The move also reflects the growing role of Asia-based innovators and implementers in Sisvel licensing programmes. The localised sites will enable more SEP licensing stakeholders to access patent pool information and programme details in their native languages. All versions of the website will be updated continuously to carry the full range of Sisvel news and insights. “Sisvel is deeply embedded in the markets where we operate,” says Sisvel Executive Head of Brand Giulia Dini. “Our expanded online presence in Asia, which also includes the recent launch of an official WeChat channel, aligns with our growing physical footprint in the region. We look forward to driving the global conversation on patent licensing and innovation.” In 2025, Sisvel appointed senior executives to run its operations in Japan and China. The
In the age of AI agents, Splio makes prediction the foundation of CRM and launches its AI-first CRM12.2.2026 10:30:00 EET | Press release
Splio announces the launch of its AI-first CRM powered by Tinyclues AI. Now integrated at the core of the platform, predictive AI helps brands orchestrate and personalize their communications at scale across every channel (email, SMS, RCS, WhatsApp...). Splio also unveils "Ask My CRM," its new AI agent designed as an intelligent marketing copilot that, plugged into each brand's customer data, makes customer knowledge easier to access, and speeds up day-to-day CRM management, from analysis to actionable recommendations. Splio made the strategic choice early on to invest in AI, especially with the acquisition of Tinyclues in 2023, to get ahead of rapid changes in the CRM Market. Today, the company runs an AI-first model with 30% of its annual recurring revenue coming from its AI offerings. Companies such as Air France, Fnac Darty, SNCF Connect, Samsung, as well as ETAM, Maisons du Monde, Mademoiselle bio, and Cyrillus in retail, already rely on Tinyclues AI on a daily basis. "We quickly
Stafford Capital Partners Announces New Renewable Energy Investment Strategy with Dedicated Team12.2.2026 10:00:00 EET | Press release
Stafford Capital Partners (“Stafford”), a leading international private markets investment and advisory firm, today announced the launch of a new strategy focused on the renewable energy sector. This initiative leverages the ongoing transformation and rapid growth within the renewables market, targeting the revamping and repowering of existing renewable assets to deliver compelling risk-adjusted returns while accelerating the transition to a low-carbon economy. This new strategic initiative further strengthens Stafford’s position in the global infrastructure investment market, providing institutions with access to a pioneering investment approach to renewable investing. This mirrors the differentiated approach Stafford has taken in developing its secondary market strategies across its real assets platform. The implementation of this strategy is driven by the integration of a dedicated 11-person team, based in Milan and Zurich, led by Angelo Prete. Stafford has worked successfully with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom